Obvious Ventures

Tracked participation in 3 Atlas companies, with 0 explicitly attributed leads.

3portfolio companies

5round participations

0lead positions

Jan 2026latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

BBoltz$125MJan 2026 → Jan 20261 roundParticipant—

DDexterityPhysical AIDexterity is a private robotics and “Physical AI” company building enterprise industrial robots and a software…$1.7Bvaluation$357.4MraisedRecent roundsRegulation D exempt offering (follow-on; series designation not stated in Form D) · Jun 2026$5MSeries C - II · Jun 2026$5M · Lightspeed Venture Partners, Matter Venture PartnersSeries C · Mar 2025$95M · led by Lightspeed Venture Partners, Sumitomo CorporationDexterity$1.4BJul 2020 → Oct 20212 roundsParticipant—

RRecursionScienceRecursion is a clinical-stage TechBio company building an industrialized, AI-native drug discovery and development…$938.3MraisedRecent roundsPublic offering (underwritten) · Jun 2024$200M · Public shareholders (offering investors)Strategic investment (private investment in public equity / PIPE) · Jul 2023$50M · led by NVIDIAInitial Public Offering (IPO) / Public offering (pricing) · Apr 2021$436.4M · Baillie Gifford & Co. (clients incl. Scottish Mortgage Investment Trust plc), Mubadala Investment Company (entities affiliated) +1Recursion—Oct 2016 → Sep 20202 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Jan 08, 2026BBoltzSeed$28M$125MParticipant

Source ↗+1 ↗

Oct 13, 2021DDexterityPhysical AIDexterity is a private robotics and “Physical AI” company building enterprise industrial robots and a software…$1.7Bvaluation$357.4MraisedRecent roundsRegulation D exempt offering (follow-on; series designation not stated in Form D) · Jun 2026$5MSeries C - II · Jun 2026$5M · Lightspeed Venture Partners, Matter Venture PartnersSeries C · Mar 2025$95M · led by Lightspeed Venture Partners, Sumitomo CorporationDexteritySeries B$140M$1.4BParticipant

Source ↗+1 ↗

Sep 09, 2020RRecursionScienceRecursion is a clinical-stage TechBio company building an industrialized, AI-native drug discovery and development…$938.3MraisedRecent roundsPublic offering (underwritten) · Jun 2024$200M · Public shareholders (offering investors)Strategic investment (private investment in public equity / PIPE) · Jul 2023$50M · led by NVIDIAInitial Public Offering (IPO) / Public offering (pricing) · Apr 2021$436.4M · Baillie Gifford & Co. (clients incl. Scottish Mortgage Investment Trust plc), Mubadala Investment Company (entities affiliated) +1RecursionSeries D$239M—Participant

Source ↗+1 ↗

Jul 23, 2020DDexterityPhysical AIDexterity is a private robotics and “Physical AI” company building enterprise industrial robots and a software…$1.7Bvaluation$357.4MraisedRecent roundsRegulation D exempt offering (follow-on; series designation not stated in Form D) · Jun 2026$5MSeries C - II · Jun 2026$5M · Lightspeed Venture Partners, Matter Venture PartnersSeries C · Mar 2025$95M · led by Lightspeed Venture Partners, Sumitomo CorporationDexteritySeed and Series A$56.2M—Participant

Source ↗

Oct 03, 2016RRecursionScienceRecursion is a clinical-stage TechBio company building an industrialized, AI-native drug discovery and development…$938.3MraisedRecent roundsPublic offering (underwritten) · Jun 2024$200M · Public shareholders (offering investors)Strategic investment (private investment in public equity / PIPE) · Jul 2023$50M · led by NVIDIAInitial Public Offering (IPO) / Public offering (pricing) · Apr 2021$436.4M · Baillie Gifford & Co. (clients incl. Scottish Mortgage Investment Trust plc), Mubadala Investment Company (entities affiliated) +1RecursionSeries A$12.9M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗+1 ↗

Source ↗

Jan 08, 2026BBoltzSeed$28M$125MParticipant

Source ↗+1 ↗

Source ↗